Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H2 2017, provides an overview of the Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline landscape.
Avian influenza A (H7N9) is a subtype of influenza viruses. This infection is seen both in humans and birds. Infection is caused when a person is exposure to infected poultry or contaminated environments. Symptoms include fever, cough that produces sputum, headache, myalgia and general malaise. Treatment includes antiviral drugs
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H7N9 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 8, 11 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 2 and 4 molecules, respectively.
Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H7N9 Subtype Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
AusBio Ltd
Beijing Minhai Biotechnology Co Ltd
Cocrystal Pharma Inc
EpiVax Inc
Genentech Inc
iBio Inc
Inovio Pharmaceuticals Inc
Karyopharm Therapeutics Inc
Medicago Inc
Medigen Vaccine Biologics Corp
Moderna Therapeutics Inc
NanoViricides Inc
Novavax Inc
Ology Bioservices Inc
Sanofi Pasteur SA
Shionogi & Co Ltd
VirionHealth Ltd
Vivaldi Biosciences Inc
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Influenza A Virus, H7N9 Subtype Infections - Overview
Influenza A Virus, H7N9 Subtype Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Influenza A Virus, H7N9 Subtype Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Influenza A Virus, H7N9 Subtype Infections - Companies Involved in Therapeutics Development
AusBio Ltd
Beijing Minhai Biotechnology Co Ltd
Cocrystal Pharma Inc
EpiVax Inc
Genentech Inc
iBio Inc
Inovio Pharmaceuticals Inc
Karyopharm Therapeutics Inc
Medicago Inc
Medigen Vaccine Biologics Corp
Moderna Therapeutics Inc
NanoViricides Inc
Novavax Inc
Ology Bioservices Inc
Sanofi Pasteur SA
Shionogi & Co Ltd
VirionHealth Ltd
Vivaldi Biosciences Inc
Influenza A Virus, H7N9 Subtype Infections - Drug Profiles
AT-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
baloxavir marboxil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-42344 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H7N9] (monovalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H7N9] (monovalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H7N9] (monovalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H7N9] (monovalent) vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H7N9] (monovalent) vaccine 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H7N9] (split virion) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H7N9] (virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H7N9] (virus like particle, monovalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H7N9] (whole virion) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H7N9] (whole virion) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H7N9] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H7N9] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H7N9] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H7N9] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H7N9] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H7N9] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H7N9] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H7N9] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H7N9] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MD-2009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit Hemagglutinin for Influenza Virus A Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mRNA-1851 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NVINF-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NVINF-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Target Sialic Acid Receptor for Influenza A Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Neuraminidase A for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
verdinexor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VH-244 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Influenza A Virus, H7N9 Subtype Infections - Dormant Projects
Influenza A Virus, H7N9 Subtype Infections - Product Development Milestones
Featured News & Press Releases
Sep 08, 2017: Shionogi to Present New Data on S-033188, a Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, at the 6th European Scientific Working Group in Influenza Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Influenza A Virus, H7N9 Subtype Infections - Pipeline by AusBio Ltd, H2 2017
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2017
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Cocrystal Pharma Inc, H2 2017
Influenza A Virus, H7N9 Subtype Infections - Pipeline by EpiVax Inc, H2 2017
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Genentech Inc, H2 2017
Influenza A Virus, H7N9 Subtype Infections - Pipeline by iBio Inc, H2 2017
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, H2 2017
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Karyopharm Therapeutics Inc, H2 2017
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Medicago Inc, H2 2017
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Medigen Vaccine Biologics Corp, H2 2017
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Moderna Therapeutics Inc, H2 2017
Influenza A Virus, H7N9 Subtype Infections - Pipeline by NanoViricides Inc, H2 2017
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Novavax Inc, H2 2017
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Ology Bioservices Inc, H2 2017
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Sanofi Pasteur SA, H2 2017
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Shionogi & Co Ltd, H2 2017
Influenza A Virus, H7N9 Subtype Infections - Pipeline by VirionHealth Ltd, H2 2017
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Vivaldi Biosciences Inc, H2 2017
Influenza A Virus, H7N9 Subtype Infections - Dormant Projects, H2 2017
List of Figures
Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
